Introduction
A ntimicrobial resistance (AMR) has been described as one of the major threats for public health in the 21st century and sparked concerns about the possibility of a post-antibiotic era, in which many infections are no longer treatable.
1,2 Such a development would not only have detrimental effects on patient care, but may also significantly affect public health, agriculture, as well as economic growth and national security. 3, 4 Over the past few years, the challenge of AMR has increasingly been recognized by policy makers. The World Health Organization (WHO) recently presented its new global action plan on AMR, 5 and a number of national and international initiatives aim to incentivize the development of new antibiotics. [6] [7] [8] Yet since one of the major causes of AMR is the overprescription and overconsumption of antibiotics, comprehensive response plans to preserve antibiotic effectiveness do not focus solely on the development of new drugs. They also include a wide range of measures, including antimicrobial resistance surveillance, infection control and, importantly, the promotion of 'rational' use of antibiotics. 1 In this paper, we argue that rational use policies raise ethical concerns when they involve delaying or withholding access to antibiotics that are known to be clinically beneficial for patients. Based on an analogy to clinical research, we present an ethical framework for rational antibiotic use that allows clinicians and policy makers to address these concerns.
Rational use of antibiotics
The promotion of 'rational' antibiotic use-sometimes referred to as prudent or appropriate use-is a key component of many response plans to AMR. [9] [10] [11] [12] [13] The WHO has provided the most widely cited definition for the rational use of medicines, including antibiotics, which requires that 'patients receive medications appropriate to their clinical need, in doses that meet their own individual requirements, for an adequate period of time, and at the lowest cost to them and their community.' 14 Elsewhere, WHO has described appropriate antibiotic use specifically as the 'cost-effective use of antimicrobials which maximizes clinical therapeutic effect while minimizing drugrelated toxicity and the development of antimicrobial resistance.' 15 Most concise is the definition provided by the Alliance for the Prudent Use of Antibiotics (APUA), which defines rational use as 'the right drug for the right condition for the right amount of time.' 16 Notwithstanding some differences in meaning, these definitions all delineate those kinds of antibiotic use that are clearly 'irrational'-namely obvious instances of overuse or misuse. There is a wide array of interventions designed to reduce such irrational use, and it appears that restrictive measures, which limit the availability of antibiotics, have a higher chance of success than information campaigns or educational interventions that teach prescribing clinicians about AMR. 17, 18 In many instances, restrictive measures appear to be a promising and effective way of reducing irrational antibiotic use. For instance, recent research has shown that antibiotic prescribing in primary care can be reduced substantially, without a negative effect on clinical outcomes, through the practice of delayed prescribing where patients receive a prescription that they can-but often do not-use at the pharmacy if symptoms persist a few days later.
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Methods
Ethical analysis of challenging instances of rational use
The rational use of antibiotics has clear benefits for patients and public health-and is therefore ethically justified or even mandatory-where it avoids clinically unnecessary or inappropriate antibiotic prescribing. However, rational use raises complex ethical questions when withholding or delaying a beneficial antibiotic places patients at risk. In other words, rational use is uncontroversial as long as it applies solely to reducing the wasteful use of drugs -but it may also involve instances in which patients are denied access to a course of treatment that may have reduced some health risk they are faced with. 22 One example for this are resistance thresholds in the community that inform antibiotic choice. For example, clinical practice guidelines for treating community-acquired pneumonia recommend the use of macrolides until a local resistance threshold of 25% is reached. Only then should clinicians switch to more effective second-line drugs. 23 Since a delayed switch to second-line drugs negatively affects clinical outcomes in some patients, some estimate that such guidelines have carried a mortality risk of more than 1% for patients. 23 In these and comparable instances, the rational use of antibiotics confronts clinicians with an ethical conflict between promoting their present patients' best clinical interests and helping to maintain effective antibiotic treatments for future patients. 24 This conflict seems particularly stark because the contribution of any individual course of antibiotics to the emergence of AMR is likely to be infinitely small and neither necessary nor sufficient for halting its progression. By contrast, the benefits of antibiotic treatment for the present patient are immediate and often directly measurable.
Bioethicists have started to discuss the ethical conflict for clinicians who restrict antibiotic use with the goal of tackling AMR. 22, 25, 26 However, in this literature, frameworks supplying practical guidance on how to manage this conflict are still largely lacking. Moreover, at the clinical and policy level, it remains an open question whether and when it is acceptable to implement the rational antibiotic use that compromises the present patients' best clinical interests. Many policy documents either lack explicit discussion of any ethical challenges, or the ethical discussion is narrowly disease-and pathogen-specific. 10, 15, 27, 28 What is therefore needed is a more substantial analysis of whether and when it is acceptable to restrict antibiotic use with the goal of curbing AMR, even when doing so poses risks to present patients and thereby compromises their best clinical interests, and a translation of the results of such analysis into policy development and, ultimately, into practice.
The analogy to clinical research
To address this question, it is helpful to consider another situation in which clinicians are justified to expose patients to some risks with the goal of benefiting future populations-namely clinical research. Clinician-investigators routinely perform research procedures that do not promote the best clinical interests of the present patientparticipant. In fact, the majority of clinical trials involve procedures without a prospect of clinical benefit that are performed to answer research questions, not to inform decisions about patient care. For example, most clinical trials involve additional blood draws, biopsies or imaging procedures that serve only to test the safety and efficacy of an investigational drug. It is appropriate for clinician-investigators to perform these procedures-and thereby deviate from the general principle that clinicians should always act in the best interests of the present patient-because research generates generalizable knowledge to improve the care of future patients. 29, 30 The social value of research justifies exposing patient-participants to some level of research risk.
Restricting antibiotic use to curb future effects of AMR is similar to clinical research in a key respect; just like in research, clinicians impose risks of harm on the present patient for the uncertain benefits of future patients. It is not certain that any given clinical trial generates findings that make a significant contribution to improving the care of future patients, nor does the participation of any single participant make a significant difference to the value of a given trial. Yet without sufficient overall participation, clinical trials-and clinical research more generally-would fail to realize their social value. Analogously, it is not certain that restricting antibiotic use will make a significant contribution to addressing AMR, nor does restricting a single patient's access to antibiotics lead to a measurable effect on the overall level of AMR. Yet reducing antibiotic prescriptions overall is a key component of strategies for curbing AMR and ensuring that bacterial infections can still be treated effectively in the future. 2, 31 Thus, since it is acceptable for clinician-investigators to impose some risks on patient-participants given the important social value of clinical research, 29, 30 it should also be acceptable to impose some risks on patients in order to tackle the major public health threat of AMR.
Importantly, there is a long-standing debate about acceptable research risks and our judgments in the context of clinical research are relatively considered. 29, 30, 32 Clinical research therefore fulfils the criteria for valid analogies 33 : it shares a key similarity with restricting antibiotic use in order to curb AMR, and it constitutes an appropriate exception from the general principle that clinicians should always act in the best interests of the present patient. This suggests that judgments about acceptable risk in clinical research can be drawn upon to evaluate the acceptability of imposing risks on present patients with the goal of curbing AMR.
Results
An ethical framework for evaluating rational antibiotics use
For clinician-researchers to be justified to impose risks on patientparticipants in clinical trials, certain conditions must be met. The research must be scientifically valid and socially valuable; the risks to participants have to be minimized and reasonable in relation to the potential clinical benefits for them and/or the social value of the research; and, when participants cannot or do not consent, any risks they assume should be no greater than minimal or, in cases of compelling social value, no greater than a minor increase over minimal risk. 29, 30 To spell out what these conditions imply in practice, a systematic framework for evaluating the risks and potential benefits of clinical research has been developed based on prominent research ethics guidelines and literature. 34 This framework can be usefully adapted to evaluate the risks of clinical practice guidelines or policies that promote rational antibiotic use by either delaying or withholding access to clinically beneficial antibiotic treatments. We suggest that this framework should be used as a basis for developing future guidance in this area.
The framework consists of six practical steps (table 1 and Supplementary Appendix S1): (1) Ensure and enhance the social value of the given rational antibiotic use policy; (2) identify the policy interventions; (3) evaluate and reduce the risks to patients; (4) evaluate and enhance the potential benefits for patients; (5) evaluate whether the policy interventions pose 'net risks' (i.e. the risks of the policy are not offset by potential clinical benefits for patients) and (6) evaluate whether the net risks are justified by the policy's social value.
All six steps consist of at least two sub-steps. While all of these sub-steps are important, some deserve particular attention.
Step 1 includes the requirement that a given policy's social value, namely its potential contribution to curbing AMR, should be enhanced by conducting research on the policy's implementation. This is both to ensure that the policy-for example, delaying or withholding antibiotics for lower respiratory tract infections (LRTIs)-is indeed effective and to enhance our knowledge of AMR. Evidence from accompanying research should inform regular re-evaluations of the policy.
The second step focuses on identifying how the care of patients under the policy differs from routine standard care. For example, if antibiotic use for LRTIs was restricted, patients might be informed about signs of pneumonia or empyema in writing, rather than verbally as in standard practice, so as to ensure they know when to seek expert advice and thereby reduce risks. However, written Ideal social arbiter might recommend the policy, given the importance of curbing antimicrobial resistance and the limited net risks to patients Notes and Sources: The framework is adapted from an existing framework for risk-benefit evaluations in biomedical research [34; see Supplementary Appendix S1 for additional details]. Example: hypothetical policy to restrict antibiotics use (delayed or no prescription) for lower respiratory tract infections (LRTIs). Ã: Research to evaluate the impact of restricted antibiotics use for a given condition has to be judged based on standard ethical criteria for research.
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information can cause anxiety in patients that needs to be managed. This illustrates the importance of identifying all policy interventions-from limiting antibiotic access to supplementary interventions aimed at reducing the associated risks for patients-in order to comprehensively evaluate the risks and potential benefits of the policy. The third step includes the requirement that the risks of all policy interventions be reasonably reduced. If antibiotic use for LRTIs was restricted, it would have to be ensured that serious harms, should they occur, are adequately managed at no financial cost to the patient. For example, early treatment of empyema would need to be guaranteed. Moreover, patient groups at increased risk of serious harm (e.g. patients with immunodeficiency) should either be actively monitored or excluded from the policy. Guidelines should also instruct clinicians to exercise their judgment in individual cases.
Step 4 requires evaluating, based on the available evidence, to what extent patients could benefit clinically from the given rational use policy. For example, not receiving antibiotics for LRTIs means avoiding their side effects and reducing the risk of infection with resistant pathogens, such as Clostridium difficile.
Step 4 also includes the requirement to enhance any potential clinical benefits to patients from the policy, such as the introduction of a non-routine physiotherapy session to help manage LRTI symptoms.
Step 5 requires judging, again based on the available evidence, whether the risks of each individual policy intervention exceed the intervention's potential clinical benefits and thereby pose 'net risks' for patients. One way of making this determination is to ask whether an 'informed clinician' who is committed solely to the promoting the patients' best clinical interests would recommend that they undergo the intervention in question. 34 If the clinician recommends delayed or no antibiotic treatment for LRTIs, for example, a respective policy intervention would promote patients' best clinical interests and thus not pose any net risks. Similarly, the intervention would not pose net risks if the clinician was indifferent between immediate, delayed or no antibiotics for LRTIs, as this would indicate that delaying or withholding antibiotic treatment would neither undermine nor promote patients' best clinical interests. In general, an informed clinician is indifferent between immediate, delayed or no treatment for LRTIs when there is a state of genuine uncertainty-also known as 'clinical equipoise'-within the community of medical experts as to which of these treatment options best promotes the patients' clinical interests. 35 Whenever a policy intervention does not pose net risks, its riskbenefit profile is acceptable and-assuming the requirements of the previous steps are satisfied-it needs no further evaluation.
However, most rational use policies that restrict antibiotic use pose some level of net risk to patients. That is, in most cases, delaying or withholding antibiotics poses risks to patients that are not offset by the clinical benefits of avoiding treatment and an informed clinician would therefore advise against this intervention. Accordingly, the notion of 'clinical equipoise' rarely applies to such policies. Whenever a policy intervention poses net risks, these risks require further evaluation.
Finally, whether any 'net risks' to patients are justified by the social value of the given policy (step 6) requires judgment on a case-by-case basis. Judgements depend on numerous factors, including the level and type of risk to patients and the certainty regarding the policy's feasibility and impact. Given that AMR is a major public health threat, some level of net risks to patients seems justified. However, in view of the significant uncertainty about how restricted antibiotic use will affect AMR, only policies with overall limited net risks seem acceptable at this point. This is especially true when one considers that rational use programmes need to be implemented as widely as possible in order to be effective-and in practice widespread implementation is likely to be feasible only when patients are not asked to give their informed consent to having antibiotic treatment withheld or delayed.
This suggests that another comparison with clinical research could be instructive. In particular, the 'minimal risk' and 'minor increase over minimal risk' thresholds are commonly used in the research context in order to protect participants who cannot give their own informed consent, such as children or patients with dementia, from being exposed to excessive net research risks. 34 While the precise interpretation of these thresholds remains contested, most existing definitions converge on equating minimal risks-or a minor increase above minimal risks-with low likelihoods of serious and moderate harm and modest likelihoods of small harm. 36 Using these thresholds from clinical research as a preliminary guide, net risks such as those reported for delayed antibiotics use for LRTIs (i.e. up to 10% risk of complications such as empyema or pneumonia) may be justified in light of the importance of preserving antibiotic effectiveness. However, more research on the risks of restricted antibiotic use and thresholds of acceptable risk in this context are necessary.
Conclusion
For clinicians, efforts to curb the effect of AMR through the rational use of antibiotics can present a particular problem because policies to restrict antibiotic use often put present patients at risk.
Exceptions from the general norm that clinicians should always act in the best interests of the present patient need to be carefully developed and managed. In this paper, based on an analogy to clinical research, we present an ethical framework that enables an explicit and practice-oriented ethical evaluation of the net risks involved in policies that restrict antibiotic use with the goal of addressing AMR. Because such evaluation requires judgments about complex empirical facts and normative questions, it is essential that policies or clinical practice guidelines that delay or withhold antibiotics are developed transparently and with the involvement of patients, clinicians and other relevant stakeholders. This involvement would not only improve the quality of deliberations, but also help to ensure the fairness and legitimacy of the resulting policies and their successful implementation.
Finally, the rational use of antibiotics can only be one part of a comprehensive strategy to address the danger of AMR. Other measures have to be pursued with equal urgency, including better infection control, comprehensive strategies to reduce antibiotic use in animals, and the development of new antibiotics.
Key points
To preserve antibiotic effectiveness, clinical practice guidelines and health policy documents call for the 'rational use' of antibiotics, which aims to reduce unnecessary or minimally effective antibiotic use. However, implementing rational use programmes can lead to ethical conflicts between promoting the best clinical interests of present patients and preserving antibiotic effectiveness for future use, as they sometimes place present patients at risk of harm. This ethical dilemma for clinicians, patients and policy makers has so far not been adequately addressed. In this paper, we develop an ethical framework that allows clinicians and policy-makers to evaluate the risks of policies for rational antibiotic use in six practical steps. This framework can help guide clinical practice and health policy by addressing the ethical conflicts in preserving antibiotic effectiveness for future patients.
